Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in k-ras/b-raf wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or without bevacizumab in k-ras mutant patients as neoadjuvant treatment in patients with non- resectable colorectal liver metastases

X
Trial Profile

Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in k-ras/b-raf wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or without bevacizumab in k-ras mutant patients as neoadjuvant treatment in patients with non- resectable colorectal liver metastases

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms AIO CELIM2-study
  • Most Recent Events

    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 10 Feb 2020 Status changed from active, no longer recruiting to discontinued.
    • 09 Sep 2019 Planned End Date changed from 1 Jul 2020 to 1 Dec 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top